madman
Super Moderator
Here are the key points from the video titled "Once-Weekly Tirzepatide for Obesity | NEJM":
The type 2 diabetes drug tirzepatide has been reported to induce weight loss in patients with diabetes. A new randomized trial reports weight loss with tirzepatide in patients without diabetes. These findings are summarized in a short video.
- Study Objective: The trial investigated the effectiveness of the type 2 diabetes drug, tirzepatide, in inducing weight reduction in adults with obesity or overweight plus a weight-related complication, but without diabetes.
- Trial Design: This was an international phase 3, double-blind, randomized trial involving 2,539 adults who were assigned to receive either 5, 10, or 15 milligrams of tirzepatide or a placebo, along with lifestyle intervention.
- Primary Endpoints: Tirzepatide showed a significant weight reduction compared to placebo. Mean weight reduction ranged from 15% to 21% with tirzepatide, compared to 3% with placebo. Additionally, a higher percentage of participants on tirzepatide lost at least 5% of their body weight by week 72 compared to those on placebo.
- Adverse Events: The most common adverse events were gastrointestinal issues such as nausea, diarrhea, and constipation. These were typically transient and mild to moderate in severity, occurring mainly during dose escalation.
- Conclusion: All three doses of tirzepatide provided meaningful and sustained weight reduction in adults with obesity without diabetes. Full trial results are available on the NEJM website.
The type 2 diabetes drug tirzepatide has been reported to induce weight loss in patients with diabetes. A new randomized trial reports weight loss with tirzepatide in patients without diabetes. These findings are summarized in a short video.
Last edited by a moderator:
